News: Sanofi SA (SNY)

SNY on New York Consolidated

56.43USD
12 Sep 2014
Price Change (% chg)

$0.70 (+1.26%)
Prev Close
$55.73
Open
$56.00
Day's High
$56.49
Day's Low
$55.83
Volume
595,981
Avg. Vol
1,097,298
52-wk High
$56.49
52-wk Low
$47.06

Search Stocks
Select another date:

Sat, Sep 13 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - (This story corrects the Sept.11 story. In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara)

CORRECTED-Sanofi aims to grow Genzyme unit with new drugs and acquisitions

(Corrects Sept.11 story. In 10th paragraph, quote should be attributed to Bill Sibold, not Mike Panzara)

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS, Sept 11 - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

Lilly, Boehringer copy of Sanofi's insulin gets EU approval

- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.

Lilly, Boehringer copy of Sanofi's insulin gets EU approval

Sept 10 - Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus.

Euro's slide revives hopes of European corporate profits recovery

* Recent drop in euro to translate into 3-6 pct rise in earnings

Lilly's diabetes drug trumps Sanofi's in late-stage trials

- Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.

Lilly's diabetes drug trumps Sanofi's in late-stage trials

Sept 4 - Eli Lilly and Co said its diabetes drug was more effective than Sanofi SA's approved drug, Lantus, in reducing blood sugar levels in late-stage trials.

Select another date:
Search Stocks